FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387221879> ?p ?o ?g. }

• W4387221879 abstract "Globally, cardiovascular disease (CVD) continues to be the primary cause of morbidity and mortality. The risk of cardiovascular disease is markedly increased in individuals with type 2 diabetes mellitus (T2DM), making managing cardiovascular health a top priority. Initially developed for their glucose-lowering properties, sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a transformative class of pharmaceuticals with profound cardiovascular benefits that extend far beyond glycemic control. One of the most striking findings is the substantial reduction in major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular mortality, observed in clinical trials evaluating SGLT2 inhibitors. These extraordinary cardioprotective effects are demonstrated by landmark trials such as EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58, which are discussed in detail. In addition, SGLT2 inhibitors have demonstrated positive outcomes in heart failure (HF) with reduced ejection fraction, which has led to their incorporation into HF treatment guidelines. SGLT2 inhibitors offer renoprotection by delaying the progression of diabetic kidney disease, reducing albuminuria, preserving glomerular filtration rates, and their immediate cardiovascular benefits. We investigate the potential mechanisms underlying these renal benefits, focusing on the role of hemodynamic alterations and intraglomerular pressure reduction. In addition, SGLT2 inhibitors have a distinct diuretic effect that can contribute to volume reduction and symptom alleviation in patients with heart failure (HF). This diuretic action, distinct from conventional diuretics, warrants additional research to optimize their use in T2DM and HF patients. The risk of euglycemic diabetic ketoacidosis, genital mycobacterial infections, and bone fractures are also discussed. Understanding these issues is essential for making educated clinical decisions. In conclusion, SGLT2 inhibitors have transcended their initial function as anti-diabetic agents to become essential components of cardiovascular and renal protection strategies in T2DM patients. Their diverse benefits, which include cardioprotection, renoprotection, and the potential for HF management, highlight their potential to transform cardiovascular medicine. Optimizing the use of SGLT2 inhibitors in clinical practice bears the promise of improved cardiovascular outcomes for patients with T2DM and beyond as we navigate this changing landscape." @default.
• W4387221879 created "2023-10-01" @default.
• W4387221879 creator A5003599736 @default.
• W4387221879 creator A5003960379 @default.
• W4387221879 creator A5005295763 @default.
• W4387221879 creator A5010967231 @default.
• W4387221879 creator A5013801676 @default.
• W4387221879 creator A5015228661 @default.
• W4387221879 creator A5020376352 @default.
• W4387221879 creator A5024614732 @default.
• W4387221879 creator A5038320837 @default.
• W4387221879 creator A5040055972 @default.
• W4387221879 creator A5041686449 @default.
• W4387221879 creator A5050453763 @default.
• W4387221879 creator A5078427149 @default.
• W4387221879 creator A5085591889 @default.
• W4387221879 creator A5087846349 @default.
• W4387221879 date "2023-09-30" @default.
• W4387221879 modified "2023-10-01" @default.
• W4387221879 title "Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management" @default.
• W4387221879 cites W2119981294 @default.
• W4387221879 cites W2146264128 @default.
• W4387221879 cites W2147602249 @default.
• W4387221879 cites W2147663252 @default.
• W4387221879 cites W2153839551 @default.
• W4387221879 cites W2168307999 @default.
• W4387221879 cites W2572666871 @default.
• W4387221879 cites W2626446274 @default.
• W4387221879 cites W2765097799 @default.
• W4387221879 cites W2772204795 @default.
• W4387221879 cites W2774743973 @default.
• W4387221879 cites W2888544493 @default.
• W4387221879 cites W2899764361 @default.
• W4387221879 cites W2900413769 @default.
• W4387221879 cites W2901368325 @default.
• W4387221879 cites W2914789585 @default.
• W4387221879 cites W2939222610 @default.
• W4387221879 cites W2972869264 @default.
• W4387221879 cites W3037508799 @default.
• W4387221879 cites W3088173406 @default.
• W4387221879 cites W3093042356 @default.
• W4387221879 cites W3094257978 @default.
• W4387221879 cites W3112405194 @default.
• W4387221879 cites W3120821309 @default.
• W4387221879 cites W3159533839 @default.
• W4387221879 cites W3173377533 @default.
• W4387221879 cites W3200644591 @default.
• W4387221879 cites W4200250603 @default.
• W4387221879 cites W4224290456 @default.
• W4387221879 cites W4238714725 @default.
• W4387221879 cites W4285299995 @default.
• W4387221879 cites W4293353625 @default.
• W4387221879 cites W4308054827 @default.
• W4387221879 cites W4324129766 @default.
• W4387221879 cites W4384067472 @default.
• W4387221879 cites W4385326105 @default.
• W4387221879 cites W4385986619 @default.
• W4387221879 cites W4386050664 @default.
• W4387221879 cites W4386802576 @default.
• W4387221879 doi "https://doi.org/10.7759/cureus.46243" @default.
• W4387221879 hasPublicationYear "2023" @default.
• W4387221879 type Work @default.
• W4387221879 citedByCount "0" @default.
• W4387221879 crossrefType "journal-article" @default.
• W4387221879 hasAuthorship W4387221879A5003599736 @default.
• W4387221879 hasAuthorship W4387221879A5003960379 @default.
• W4387221879 hasAuthorship W4387221879A5005295763 @default.
• W4387221879 hasAuthorship W4387221879A5010967231 @default.
• W4387221879 hasAuthorship W4387221879A5013801676 @default.
• W4387221879 hasAuthorship W4387221879A5015228661 @default.
• W4387221879 hasAuthorship W4387221879A5020376352 @default.
• W4387221879 hasAuthorship W4387221879A5024614732 @default.
• W4387221879 hasAuthorship W4387221879A5038320837 @default.
• W4387221879 hasAuthorship W4387221879A5040055972 @default.
• W4387221879 hasAuthorship W4387221879A5041686449 @default.
• W4387221879 hasAuthorship W4387221879A5050453763 @default.
• W4387221879 hasAuthorship W4387221879A5078427149 @default.
• W4387221879 hasAuthorship W4387221879A5085591889 @default.
• W4387221879 hasAuthorship W4387221879A5087846349 @default.
• W4387221879 hasBestOaLocation W43872218791 @default.
• W4387221879 hasConcept C126322002 @default.
• W4387221879 hasConcept C127413603 @default.
• W4387221879 hasConcept C134018914 @default.
• W4387221879 hasConcept C164705383 @default.
• W4387221879 hasConcept C177713679 @default.
• W4387221879 hasConcept C2775887513 @default.
• W4387221879 hasConcept C2776174234 @default.
• W4387221879 hasConcept C2777099384 @default.
• W4387221879 hasConcept C2777180221 @default.
• W4387221879 hasConcept C2777422806 @default.
• W4387221879 hasConcept C2777451236 @default.
• W4387221879 hasConcept C2778198053 @default.
• W4387221879 hasConcept C2780473172 @default.
• W4387221879 hasConcept C2780645631 @default.
• W4387221879 hasConcept C500558357 @default.
• W4387221879 hasConcept C555293320 @default.
• W4387221879 hasConcept C71924100 @default.
• W4387221879 hasConcept C78085059 @default.
• W4387221879 hasConcept C78519656 @default.
• W4387221879 hasConcept C90466245 @default.

• next